Galenica Group

Vifor, ChemoCentryx expand kidney health alliance to include renal diseases

Tuesday, January 3, 2017

Vifor Pharma, a company of the Galenica Group, and ChemoCentryx have announced the expansion of their existing kidney health alliance to include the development and commercialization of CCX140, an orally-administered inhibitor of the chemokine receptor known as CCR2, for renal diseases. CCX140 has previously completed a successful phase II clinical trial in patients with diabetic kidney disease.

[Read More]